Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.